Parkinson’s Disease Drugs Market

Parkinson’s Disease Drugs Market by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Others), and Geography (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2088
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 173
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Parkinson’s disease drugs market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to ageing population and increasing frequency of neurological disorders.


Parkinson’s Disease Drugs Market key takeaways

Parkinson's disease is a long-term neurological disease affecting mobility. Tremor in the hands, bradykinesia, postural instability, and stiffness in the motions of body parts and muscles are all symptoms of this condition. Depression, emotional changes, urinary difficulties, disrupted sleep, dysphagia, constipation, dysarthria, and skin problems are also the symptoms. It also affects the victims' mobility and muscular control. Both motor and non-motor factors have an impact on it. Non-motor symptoms of the illness are linked to the death of neurons in non-dopaminergic regions of the nervous system, whereas motor symptoms are linked to the loss of striatal dopaminergic neurons. Certain nerve cells (neurons) in the brain eventually break down or die in Parkinson's disease. Many of the symptoms are caused by the death of neurons in your brain that generate dopamine, a chemical messenger. Dopamine deficiency produces aberrant brain activity, which leads to poor mobility and other Parkinson's disease symptoms.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing elderly population is projected to fuel the market during forecast period.
  • Increasing frequency of neurological disorders is key factor propelling the market in the coming years.
  • High price of therapy is expected to restrict the market growth.
  • Lack of competence for early diagnosis act as major challenge that can hinder the market during the forecast period.
  • R&D investment and technological advancement is expected to created lucrative opportunities for the market players.

Scope of the Report

The report on the Parkinson’s disease drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Parkinson’s Disease Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Others)

Geographical Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Teva Pharmaceuticals Industries Ltd; AbbVie Inc.; Boehringer Ingelheim GmbH; Merck & Co. Inc.; GlaxoSmithKline PLC

 

Market Segment Insights

The COMT inhibitors segment is projected to hold a major market share

In terms of mechanism of action, the Parkinson’s disease drugs market is segregated into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and others. The COMT inhibitors segment is expected to represent a key share of the market during the forecast period. The most effective treatment for Parkinson's disease motor symptoms is carbidopa-levodopa therapy. However, it has been discovered that this medicine does not work as it should. As a result, co-therapeutic drugs such as COMT (catechol-O-methyltransferase) inhibitors must be used in conjunction with carbidopa-levodopa treatment. Comtan (entacapone) and tasmar are the two most often used COMT inhibitors in the treatment of Parkinson's disease (tolcapone). Both of these medicines are used in combination with carbidopa-levodopa treatment and are available in tablet form.


Parkinson’s Disease Drugs Market by mechanism

The US is expected to dominate the market

On the basis of geography, the Parkinson’s disease drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The US is anticipated to dominate the market during the forecast period. Parkinson's disease is expected to affect 1.2 million individuals in the US during the forecast period, according to the national institute of health. As the world's population ages, the number of persons suffering from Parkinson's disease (PD) is anticipated to expand during forecast period. Factors such as increasing number of people with Parkinson's disease, as well as the availability of reimbursements and increased awareness are estimated to boost the market. Parkinson's medicine costs about USD 2,500 per year on average, while surgery for Parkinson's can cost up to USD 100,000 per patient.


Parkinson’s Disease Drugs Market by Regions

Segments

Segments Covered in the Report
The Parkinson’s disease drugs market has been segmented on the basis of

Mechanism of action

  • Dopamine Agonists
  • Anticholinergic
  • MAO-B Inhibitors
  • Amantadine
  • Carbidopa-levodopa
  • COMT Inhibitors
  • Others

Geography

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Teva Pharmaceuticals Industries Ltd
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC

Competitive Landscape

Key players competing in the Parkinson’s disease drugs market include Teva Pharmaceuticals Industries Ltd, AbbVie Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., and GlaxoSmithKline PLC.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.

Parkinson’s Disease Drugs Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Parkinson’s Disease Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Parkinson’s Disease Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Parkinson’s Disease Drugs Market - Supply Chain
  4.5. Global Parkinson’s Disease Drugs Market Forecast
     4.5.1. Parkinson’s Disease Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Parkinson’s Disease Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Parkinson’s Disease Drugs Market Absolute $ Opportunity
5. Global Parkinson’s Disease Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Parkinson’s Disease Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Parkinson’s Disease Drugs Demand Share Forecast, 2019-2026
6. North America Parkinson’s Disease Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Parkinson’s Disease Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Parkinson’s Disease Drugs Demand Share Forecast, 2019-2026
7. Latin America Parkinson’s Disease Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Parkinson’s Disease Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Parkinson’s Disease Drugs Demand Share Forecast, 2019-2026
8. Europe Parkinson’s Disease Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Parkinson’s Disease Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Parkinson’s Disease Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Parkinson’s Disease Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Parkinson’s Disease Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Parkinson’s Disease Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Parkinson’s Disease Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Parkinson’s Disease Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Parkinson’s Disease Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Parkinson’s Disease Drugs Market: Market Share Analysis
  11.2. Parkinson’s Disease Drugs Distributors and Customers
  11.3. Parkinson’s Disease Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Teva Pharmaceuticals Industries Ltd
     11.4.2. AbbVie Inc.
     11.4.3. Boehringer Ingelheim GmbH
     11.4.4. Merck & Co. Inc.
     11.4.5. GlaxoSmithKline PLC

Segments Covered in the Report
The Parkinson’s disease drugs market has been segmented on the basis of

Mechanism of action

  • Dopamine Agonists
  • Anticholinergic
  • MAO-B Inhibitors
  • Amantadine
  • Carbidopa-levodopa
  • COMT Inhibitors
  • Others

Geography

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Teva Pharmaceuticals Industries Ltd
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC

Key players competing in the Parkinson’s disease drugs market include Teva Pharmaceuticals Industries Ltd, AbbVie Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., and GlaxoSmithKline PLC.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.

Parkinson’s Disease Drugs Market by key players

Buy Report